Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004334 | PO / MO |
The patient took third dose of Vivotif a week later after second vaccine; Case reference number US-BN-2025-001544 is a spontaneous case initially received from a nurse via Communications (reference number: USBAV25-2300) on 15-Sep-2025 and concerns a 69-years-old male patient. The patient's medical history and concomitant medication were not provided. On an unspecified date, the patient took the first dose of Vivotif vaccine (batch number: 3004334) at an unknown dose, orally for the indication of pre-travel/cruise to [withheld]. On an unspecified date, reported as 48 hours after the first dose, the patient took the second dose of Vivotif vaccine (batch number: 3004334) at an unknown dose, orally. On an unspecified date, reported as a week later from the second dose, the patient took the third dose of Vivotif vaccine (batch number: 3004334) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 69-year-old male patient took the third dose of Vivotif vaccine for the indication of pre-travel/cruise to [withheld], reported as a week later from the second dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect vaccine, but to human factor. The case is non-serious.; Sender's Comments: A 69-year-old male patient took the third dose of Vivotif vaccine for the indication of pre-travel/cruise to [withheld], reported as a week later from the second dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect vaccine, but to human factor. The case is non-serious.
Comments: None.